SG10202011470UA - Compositions and methods for treating negative symptoms in non-schizophrenic patients - Google Patents
Compositions and methods for treating negative symptoms in non-schizophrenic patientsInfo
- Publication number
- SG10202011470UA SG10202011470UA SG10202011470UA SG10202011470UA SG10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA SG 10202011470U A SG10202011470U A SG 10202011470UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- negative symptoms
- schizophrenic patients
- treating negative
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000000698 schizophrenic effect Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Addiction (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662341590P | 2016-05-25 | 2016-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202011470UA true SG10202011470UA (en) | 2021-01-28 |
Family
ID=58794265
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810358YA SG11201810358YA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
SG10202011470UA SG10202011470UA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201810358YA SG11201810358YA (en) | 2016-05-25 | 2017-05-23 | Compositions and methods for treating negative symptoms in non-schizophrenic patients |
Country Status (9)
Country | Link |
---|---|
US (2) | US20190216793A1 (en) |
EP (1) | EP3463356A1 (en) |
JP (2) | JP2019516756A (en) |
KR (2) | KR20240005110A (en) |
CN (3) | CN113694065A (en) |
PH (1) | PH12018502445A1 (en) |
SG (2) | SG11201810358YA (en) |
TW (2) | TWI820001B (en) |
WO (1) | WO2017205393A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY185516A (en) | 2014-12-02 | 2021-05-19 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating schizophrenia |
CN111511353A (en) | 2017-06-21 | 2020-08-07 | 田边三菱制药株式会社 | Gastric juice resistant controlled release oral dosage form |
BR112021002654A2 (en) * | 2018-08-21 | 2021-05-04 | Minerva Neurosciences, Inc. | use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity and promote neuroprotection |
KR102360137B1 (en) * | 2020-03-25 | 2022-02-08 | 주식회사 케이티앤지 | Cartridge and Aerosol generating device comprising thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL151533A0 (en) * | 2000-02-29 | 2003-04-10 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
AU2007212349A1 (en) * | 2006-02-07 | 2007-08-16 | Mitsubishi Tanabe Pharma Corporation | 4-acylaminopyridine derivative mediated neurogenesis |
CN101273982A (en) * | 2007-03-30 | 2008-10-01 | 田边三菱制药株式会社 | Medicament for preventing or/and treating depression |
WO2012012543A1 (en) * | 2010-07-20 | 2012-01-26 | Cyrenaic Pharmaceuticals Inc. | Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders |
RS64819B1 (en) * | 2010-07-20 | 2023-12-29 | Minerva Neurosciences Inc | Methods of use of cyclic amide derivatives to treat schizophrenia and symptoms thereof |
US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
WO2015174534A1 (en) * | 2014-05-16 | 2015-11-19 | 武田薬品工業株式会社 | Nitrogen-containing heterocyclic compound |
MY185516A (en) * | 2014-12-02 | 2021-05-19 | Mitsubishi Tanabe Pharma Corp | Compositions and methods for treating schizophrenia |
-
2017
- 2017-05-23 SG SG11201810358YA patent/SG11201810358YA/en unknown
- 2017-05-23 CN CN202111014262.XA patent/CN113694065A/en active Pending
- 2017-05-23 JP JP2018561528A patent/JP2019516756A/en active Pending
- 2017-05-23 KR KR1020237043697A patent/KR20240005110A/en active Search and Examination
- 2017-05-23 EP EP17726525.3A patent/EP3463356A1/en active Pending
- 2017-05-23 CN CN201780045461.2A patent/CN109689055A/en active Pending
- 2017-05-23 KR KR1020187036656A patent/KR20190013846A/en not_active IP Right Cessation
- 2017-05-23 US US16/302,722 patent/US20190216793A1/en not_active Abandoned
- 2017-05-23 TW TW106117023A patent/TWI820001B/en active
- 2017-05-23 SG SG10202011470UA patent/SG10202011470UA/en unknown
- 2017-05-23 CN CN202111014298.8A patent/CN113908156A/en active Pending
- 2017-05-23 WO PCT/US2017/034030 patent/WO2017205393A1/en unknown
- 2017-05-23 TW TW112118953A patent/TW202335672A/en unknown
-
2018
- 2018-11-20 PH PH12018502445A patent/PH12018502445A1/en unknown
-
2022
- 2022-05-26 US US17/825,783 patent/US20230190726A1/en active Pending
- 2022-10-04 JP JP2022160201A patent/JP2022188185A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113694065A (en) | 2021-11-26 |
JP2022188185A (en) | 2022-12-20 |
TWI820001B (en) | 2023-11-01 |
CN109689055A (en) | 2019-04-26 |
US20190216793A1 (en) | 2019-07-18 |
SG11201810358YA (en) | 2018-12-28 |
TW201808288A (en) | 2018-03-16 |
PH12018502445A1 (en) | 2019-09-09 |
US20230190726A1 (en) | 2023-06-22 |
WO2017205393A1 (en) | 2017-11-30 |
CN113908156A (en) | 2022-01-11 |
KR20240005110A (en) | 2024-01-11 |
KR20190013846A (en) | 2019-02-11 |
TW202335672A (en) | 2023-09-16 |
JP2019516756A (en) | 2019-06-20 |
EP3463356A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252821A1 (en) | Compositions and methods for treating patients with rtk mutant cells | |
HK1243639A1 (en) | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders | |
HK1244461A1 (en) | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders | |
HK1244826A1 (en) | Methods and compositions for adoptive cell therapy | |
HK1243640A1 (en) | Methods and compositions for treating ulcers | |
HK1243942A1 (en) | Sunitinib formulations and methods for use thereof in treatment of glaucoma | |
IL251774A0 (en) | Methods and compositions for dosing in adoptive cell therapy | |
IL248193B (en) | Compositions for use in treating nafld and nash | |
RS59446B1 (en) | Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases | |
EP3212003A4 (en) | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders | |
SG10202011470UA (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
IL246855A0 (en) | Agents for use in the treatment of retinal inflammation | |
SI3373922T1 (en) | Compositions and methods for use in the treatment of homocystinuria | |
SI3406258T1 (en) | Medicament for use in treating gout | |
GB201621394D0 (en) | Improvements in and relating to waste treatment | |
HK1258073A1 (en) | Methods and compositions for the treatment of cytopplasmic glycogen storage disorders | |
GB201614318D0 (en) | Methods and compositions used in treating inflammatory and autoimmune diseases | |
ZA201705400B (en) | Compositions containing arsenic and their use in methods of treatment | |
PL3212280T3 (en) | Tinnitus fitting in ci and abi patients | |
GB2510477B (en) | Formulations for use in the treatment of chronic fatigue and associated conditions, etc | |
ZA201408464B (en) | Composition for the use in treatment of asthma |